Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Composition containing antidementia agent

A composition and technology for dementia, applied in the field of compositions containing anti-dementia drugs, can solve the problems of failure to improve compliance, difficulty in controlling two or more anti-dementia drugs at the same time, and achieve excellent compliance and quality, simple Convenient production method, release easy effect

Inactive Publication Date: 2008-04-23
EISIA R&D MANAGEMENT CO LTD
View PDF7 Cites 13 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Therefore, it is difficult to simultaneously control the release of two or more antidementia drugs in a single dosage form. The current situation is that there is no published literature report on the specific control method of antidementia drugs, and there is no need to improve compliance. tips, or techniques for the preparation of formulations for the combined effect of two or more antidementia drugs used simultaneously

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Composition containing antidementia agent
  • Composition containing antidementia agent
  • Composition containing antidementia agent

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0060] A fifth example is a composition containing multiple types of particles. Each type of granule can be manufactured as immediate release, sustained release, pulsed release or similar to freely establish the desired dissolution profile. For example, (1) the composition may contain immediate-release granules containing memantine hydrochloride, sustained-release granules containing donepezil hydrochloride and pulse-release granules containing memantine hydrochloride, so that after one administration, the blood concentration of memantine hydrochloride reaches The time interval between peaks can reach 8 hours or more, and donepezil hydrochloride is gradually released after administration. Alternatively, (2) a preparation form for once-a-day administration may be prepared, the preparation method comprising: making the sustained-release granules which start to be released 2 hours, 4 hours, 6 hours or 8 hours after administration contain 5 mg Adamantine, which is combined with g...

Embodiment 1

[0130] 6 g of donepezil hydrochloride (Eisai Co. Ltd.), 12 g of memantine hydrochloride (Lachema s.r.o.), 28.8 g of Ethocel 10FP (ethylcellulose, Dow Chemical Company), 36 g of Eudragit L100-55 (Röhm GmbH & Co.KG) and 45.6 lactose are mixed with each other in a granulator. An aqueous solution of 2.4 g of hydroxypropyl cellulose dissolved in an appropriate amount of pure water was added to the mixture for wet granulation, and the obtained granules were heated and dried by a disc dryer, and then sieved to obtain granules of the desired size. After sieving, 1 g of magnesium stearate was added per 109 g of granules and mixed, followed by tableting using a rotary tablet machine, thereby obtaining a compression-molded product with a diameter of 8 mm, which contained 10 mg of donepezil hydrochloride and 20 mg of memantine hydrochloride in a 220 mg tablet . Adopt Opadry yellow (Colorcon Japan Limited) to provide water-soluble film coating to the obtained product, the main component o...

Embodiment 2

[0132] 5 g of donepezil hydrochloride (Eisai Co. Ltd.), 10 g of memantine hydrochloride (Lachema s.r.o.), 20 g of cornstarch (Nihon Shokuhin Kako Co., Ltd.), 15 g of microcrystalline cellulose (Asahi Kasei Corporation) and 81.75 g of lactose in Mixed with each other in a granulator. An aqueous solution of 3.0 g of hydroxypropyl cellulose dissolved in an appropriate amount of pure water was added to the mixture for wet granulation, and the obtained granules were heated and dried by a disc dryer, and then sieved to obtain granules of the desired size. After sieving, 0.25 g of magnesium stearate was added per 134.75 g of granules and mixed, followed by tableting using a rotary tablet machine, thereby obtaining a compression-molded product with a diameter of 7 mm, which contained 5 mg of donepezil hydrochloride and 10 mg of hydrochloric acid in a 135 mg tablet Memantine. Adopt Opadry yellow (Colorcon Japan Limited) to provide water-soluble film coating to the obtained product, th...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

An object of the present invention is to provide, for the case of implementing a therapeutic method in which at least two kinds of anti-dementia drugs are used together, a composition that has a good therapeutic effect on dementia, and also gives excellent compliance. Another object of the present invention is to provide a composition containing at least two kinds of anti-dementia drugs, in which release of the anti-dementia drugs from the composition is controlled, whereby a combined effect of the anti-dementia drugs can be achieved well. Still another object of the present invention is to provide a composition for which the frequency of administration and the amount taken are reduced and hence compliance can be improved, and a method of manufacturing such a composition. According to the present invention, there is provided a composition containing at least two kinds of anti-dementia drugs; such a composition containing at least one sustained-release portion containing an anti-dementia drug; and such a composition containing at least one cholinesterase inhibitor, and at least one N-methyl-D-aspartate receptor antagonist.

Description

technical field [0001] The present invention relates to a composition containing antidementia medicine. More specifically, the present invention relates to a composition containing at least two classes of anti-dementia drugs. Background technique [0002] In recent years, care for dementia such as senile dementia and Alzheimer's dementia has become a social issue, and many drugs for treating dementia are under development. Among these drugs, donepezil is widely used as a therapeutic drug for mild to moderate Alzheimer's dementia due to its acetylcholinesterase inhibitory effect, and its dosage form is tablets or granules of its hydrochloride (trade name Aricept ( Aricept), produced by Eisai Co., Ltd.). In addition, memantine hydrochloride, which exhibits antagonistic effects on N-methyl-D-aspartate (NMDA) receptors, has also been developed as a therapeutic drug for moderate to severe Alzheimer's dementia, which is usually a film-coated tablet or Liquid dosage forms (trade...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/06A61K31/13A61K31/445A61K47/30A61P25/28
CPCA61K31/13A61K45/06A61K9/5084A61K9/2027A61K31/445A61K9/209A61K9/2054A61K9/2846A61K47/38A61K9/2866A61P25/28A61K2300/00
Inventor 木村进植木洋祐野原正美堂田征史
Owner EISIA R&D MANAGEMENT CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com